Skip to main content

Table 4 DXA at baseline and at 12 months

From: Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children

PATIENT BMC(g/cm2)
0–12 m
LMB(g)
0–12 m
FAT(g)
0–12 m
FAT (%)
0–12 m
Z-SCORE
0–12 m
BMC-age related changes(%)
0–12 m
1 0,798–0.949 26.778–29.9807 13.082–12.249 31–28 -1.05 → -3.34 90.9–83.4
2 0,731–0,748 17.687–19.909 8071–10.922 30–34 2,08 → 4,31 116,9–135
3 0,759–0,832 20.751–23.293 9579–11.409 30–31 1,8 → 2,59 116,6–121,9
4 0,803–0,868 26.856–41.913 7014–5526 20-11 -4,21 → -3,01 70,1–82,1
5 0,687–0,723 19.300–20.563 7181–7949 26–27 1,01 → 0,88 110,5–110,4
6 0,76–0,83 22.559–28.061 10.967–11.393 31-28 -1,14 → -1,25 90–89,5
7 NA-0,732 NA-21.263 NA-13.069 NA-36 NA → 1,56 NA-112,8
P 0,04 0,02 0,2 0,8 0,2 0,2
  1. BMC: bone mineral content, LMB: lean body mass, NA: not available, g: grams.